All In Biotech

NDA 206192 · Genentech INC

Cotellic

Cobimetinib Fumarate · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 10, 2015

Approved uses

4

Original approval plus efficacy supplements

Registered trials

115

10 Phase 3, 13 recruiting

FAERS reports

4,436

3,673 serious, 588 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) 1.1 Unresectable or Metastatic Melanoma COTELLIC ® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 1.2 Histiocytic Neoplasms COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.

Mechanism: Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared to either drug...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 28, 2022 Supplement 5 · Efficacy · priority review OrphanLabelLetter
  • Jul 28, 2022 Supplement 4 · Efficacy · priority review LetterLabel
  • Jan 26, 2018 Supplement 2 · Efficacy LabelLetter
  • Nov 10, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLetterLabel
1 products under this application
  • COTELLIC · COBIMETINIB FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cobimetinib" as an intervention, any sponsor and status, largest first.

All 115 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use482
  • diarrhoea446
  • rash402
  • pyrexia368
  • death253
  • nausea235
  • fatigue221
  • vomiting185
  • no adverse event183
  • acute kidney injury139
  • asthenia134
  • photosensitivity reaction133

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
201316
201426
201586
2016455
2017583
2018706
2019556
2020370
2021362
2022342
2023239
2024368
2025194
2026131

Recalls

1 FDA enforcement reports for this application.

  • Mar 13, 2017 · Class II · Terminated

    Superpotent Drug: An oversized tablet was found in a bottle.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cotellic (Cobimetinib Fumarate)

2024 spending

$8.2M

Beneficiaries

250

1,518 claims

Per beneficiary

$32,649

$124.35 per unit

View as table
YearSpending
2020$4,152,986
2021$5,315,892
2022$5,979,372
2023$6,345,616
2024$8,162,277

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 83 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.